<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03591666</url>
  </required_header>
  <id_info>
    <org_study_id>2018HNRT02</org_study_id>
    <nct_id>NCT03591666</nct_id>
  </id_info>
  <brief_title>A Study of Anlotinib in Recurrent/Metastatic Head and Neck Adenocarcinomas</brief_title>
  <official_title>A Non-randomized Phase II Study of Anlotinib in Recurrent/Metastatic Head and Neck Adenocarcinomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a non-randomized, phase II, open label study of anlotinib hydrochloride capsules in
      recurrent/metastatic adenocarcinomas of head and neck. The primary purpose of this study is
      to evaluate the efficacy of anlotinib.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 15, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>up to 24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progress free survival (PFS)</measure>
    <time_frame>up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>up to 24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">51</enrollment>
  <condition>Head and Neck Carcinoma</condition>
  <condition>Adenocarcinoma</condition>
  <condition>Recurrent Disease</condition>
  <condition>Distantly Metastatic Malignant Neoplasm</condition>
  <arm_group>
    <arm_group_label>Study Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anlotinib</intervention_name>
    <description>Anlotinib p.o. qd</description>
    <arm_group_label>Study Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically or cytologically confirmed head and neck adenocarcinoma.

          2. Patients with recurrent or metastatic head and neck adenocarcinoma who are not
             candidates for curative surgery or radiotherapy.

          3. Measurable disease per the RECIST criteria.

          4. Eastern Cooperative Oncology Group (ECOG) performance status 0-2.

          5. Provision of written informed consent.

          6. Childbearing potential either terminated by surgery, radiation, or menopause, or
             attenuated by use of an approved contraceptive method (IUD, birth control pills, or
             barrier device) during and for 3 months after completion of trial therapy.

        Exclusion Criteria:

          1. Prior treatment with Anlotinib

          2. With pleural effusion or ascites, cause respiratory syndrome

          3. Accepted the vascular endothelial growth inhibitor class targeted drug treatment of
             patients

          4. Plan to take systemic anti-tumor therapy within 4 weeks before grouping or during the
             medicine-taking period of this research, including Cytotoxic Therapy, 5.Signal
             Transduction Inhibitor, and Immunotherapy (or who use Mitomycin C within 6 weeks
             before taking the treatment with experimental drug); The patients who have already
             taken Extended Field Radiotherapy (EF-RT) within 4 weeks before grouping or Limited
             Field Radiotherapy with proposed assessment of nidus within 2 weeks before grouping

        6.Symptoms of brain metastases cannot be controlled and treated within less than 2 months
        7.severe and failed to controlled diseases 8.Occurred venous thromboembolic events within 6
        months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guopei Zhu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shengjin Dou</last_name>
    <phone>+8615800386875</phone>
    <email>doushengjin@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai ninth people's hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200011</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>July 9, 2018</study_first_submitted>
  <study_first_submitted_qc>July 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 19, 2018</study_first_posted>
  <last_update_submitted>July 9, 2018</last_update_submitted>
  <last_update_submitted_qc>July 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>head and neck adenocarcinoma</keyword>
  <keyword>Anlotinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

